FLGT Fulgent Genetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FLGT

Price (delayed)

$21.27

Market cap

$585.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.82

Enterprise value

$559.43M

?
Relative Growth: Rel. Growth: 11
Relative Strength: Rel. Strength: 61
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 19

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of ...

Highlights
Fulgent Genetics's revenue has increased by 7% YoY
FLGT's quick ratio is up by 17% since the previous quarter but it is down by 13% year-on-year
FLGT's EPS has dropped by 70% year-on-year and by 18% since the previous quarter
The net income has plunged by 65% YoY and by 14% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.fulgentgenetics.com
Peers: OBIO OM OPK NEO

Key stats

What are the main financial stats of FLGT

FLGT stock price

How has the Fulgent Genetics stock price performed over time
Intraday
-1.76%
1 week
-1.66%
1 month
6.88%
1 year
-3.05%
YTD
-19.03%
QTD
3.65%

Financial performance

How have Fulgent Genetics's revenue and profit performed over time
Revenue
$323.93M
Gross profit
$115.26M
Operating income
-$122.28M
Net income
-$84.38M
Gross margin
35.6%
Net margin
-26%
Fulgent Genetics's operating income has plunged by 68% YoY and by 15% from the previous quarter
The net income has plunged by 65% YoY and by 14% from the previous quarter
Fulgent Genetics's operating margin has plunged by 57% YoY and by 14% from the previous quarter
Fulgent Genetics's net margin has plunged by 55% YoY and by 13% from the previous quarter

Price vs fundamentals

How does FLGT's price correlate with its fundamentals

Growth

What is Fulgent Genetics's growth rate over time

Valuation

What is Fulgent Genetics stock price valuation
FLGT P/E details
P/E
N/A
P/B
0.6
P/S
1.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.73
FLGT's EPS has dropped by 70% year-on-year and by 18% since the previous quarter
The price to book (P/B) is 33% lower than the 5-year quarterly average of 0.9
The company's equity fell by 10% YoY and by 4.6% QoQ
FLGT's P/S is 16% below its 5-year quarterly average of 2.2 and 8% below its last 4 quarters average of 2.0
Fulgent Genetics's revenue has increased by 7% YoY

Efficiency

How efficient is Fulgent Genetics business performance
The return on equity has dropped by 76% year-on-year and by 18% since the previous quarter
The company's return on assets has shrunk by 71% YoY and by 16% QoQ
The company's return on invested capital has shrunk by 60% YoY and by 11% QoQ
FLGT's ROS is down by 44% year-on-year and by 8% since the previous quarter

Dividends

What is FLGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FLGT.

Financial health

How did Fulgent Genetics financials performed over time
FLGT's current ratio is up by 19% since the previous quarter and by 5% year-on-year
Fulgent Genetics's total liabilities has decreased by 17% from the previous quarter but it has increased by 6% YoY
Fulgent Genetics's debt is 100% less than its equity
The company's equity fell by 10% YoY and by 4.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.